Your session is about to expire
← Back to Search
Rivaroxaban for Cancer-related Blood Clot Prevention (TRIM-Line Trial)
TRIM-Line Trial Summary
This trial is testing if a drug can prevent blood clots in cancer patients with a central venous catheter.
TRIM-Line Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TRIM-Line Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your platelet count has been very low in the past 3 months.You are allergic to rivaroxaban.You are not expected to live for more than 3 months.I am currently taking two medications to prevent blood clots.I need blood thinners for a health condition.I have not had severe liver disease in the last 3 months.I have a condition that increases my risk of bleeding, such as recent stroke or active ulcers.I am 18 or older with cancer and had a central venous catheter placed within the last 3 days.My kidney function is severely reduced.I have not had a major bleeding event in the last 4 weeks.You have had a central venous catheter (CVC) for more than 72 hours.I have a long-term bleeding disorder.I am not taking medications like cobicistat or ketoconazole.My cancer is either basal cell or squamous cell skin cancer.
- Group 1: Control
- Group 2: Experimental
- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any opportunities for new patients to join this clinical trial?
"The clinical trial is currently active and recruiting patients, according to the information available on clinicaltrials.gov. This particular trial was first posted on October 5th, 2020, with the most recent edit taking place on October 1st of the same year."
How many individuals will be participating in this research?
"The clinical trial is, as of 10/1/2022, still recruiting the 1828 patients needed from 1 site according to information found on clinicaltrials.gov. The posting for the study went up on 10/5/2022."
Has a trial like this been done before?
"Experimental has been under investigation since as early as 2015 when Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma ran the first trial. Since that initial study with 2180 participants, Experimental received its Phase 3 drug approval in [year]. As of today, there are 62 active studies involving Experimental being conducted in 403 cities across 45 countries."
Are there any know side effects of the Experimental drug?
"There is evidence from past trials to support the safety of this experimental medication, thus it received a score of 3."
What are the goals that this clinical trial is looking to achieve?
"The purpose of this 90-day study is to prevent Major VTEs. Additionally, researchers will be evaluating for secondary objectives including PE, fatal VTEs, and ICERs."
What are some of the main purposes for using Experimental drugs?
"Experimental has shown to be an effective method of treatment for venous thromboembolism, chronic coronary artery disease, and deep vein thrombosis."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger